The purpose of this study is to explore the possible cognitive effects of oxybutynin tablets and oxybutynin gel.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
TRIPLE
Enrollment
153
capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
National City, California, United States
Unnamed facility
Maitland, Florida, United States
Unnamed facility
Naples, Florida, United States
Measure of accuracy of delayed recall name-phase association test
Time frame: one week
Effects on other cognitive domains measured by various tests
Time frame: one week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Ocala, Florida, United States
Unnamed facility
Atlanta, Georgia, United States